top of page
Cancer52 response to the NICE consultation
Please find here Cancer52's response to the NICE Methods of Technology Appraisal Consultation, which was submitted to NICE on Tuesday...
Clara Mackay appointed as interim chair of Cancer52
Cancer52 is delighted to announce that Clara Mackay, Deputy CEO of Pancreatic Cancer UK, has been appointed as interim chair of Cancer52....
Cancer52 responds to NICE consultation on Technology Appraisals Process Guide
On the basis of the increasing experience of our members with NICE Technology Appraisals Cancer52 has commented in detail on a number of...
Cancer52 publishes briefing paper on the UK Strategy for Rare Diseases
Making sure that rare cancers aren’t written out of the script Cancer52 published its briefing paper on the UK Strategy for Rare...
Cancer52 publishes briefing paper on NICE and Value Based Assessment (VBA)
Cancer52 published its briefing paper "NICE and Value Based Assessment (VBA) - NICE do it their way." NICE is due to consult on its...
Cancer52 welcomes NCIN Routes to Diagnosis research
The National Cancer Intelligence Network (NCIN) has published new research on Routes to Diagnosis (RtD) for 55 cancer sites or groups,...
100K Genome Project
In December 2013, Cancer52 wrote a letter to Sir John Chisholm, Executive Chair of Genomics England, expressing its alarm that the 100K...
Cancer52 at Macmillan Primary Care Conference - 21-22 November 2013
Cancer52 had a stand at exhibition at the MacMillan Primary Care Conference in November 2013. Visitors to the stand learned of the work...
Government agrees to full consultation of the Medical Innovation Bill
The government agreed to full consultation of the Medical Innovation Bill spearheaded by Lord Saatchi. Jeremy Hunt, the Secretary of...
NCRI and Cancer52 publish report on research spend
A new report from the National Cancer Research Institute (NCRI) and Cancer52 was published in November 2013, showing for the first time...
bottom of page